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Summary
Introduction. Valproic acid is commonly used for the treatment of epilepsy, psychiatric disorders such as 
bipolar disorders, anxiety and prophylaxis migraine. Long-term use of valproic acid is related with meta-
bolic disorders such as the increase of body weight and changes of lipid profiles which are contributed to 
cardiovascular events, however, these associations remain unclear, furthermore, the mechanisms of these 
effects have not been fully elucidated.
Aim. To summarize and discuss the potential mechanisms of valproic acid-related changes of lipid profiles 
so as to get a better understanding of the side effects of valproic acid on lipid metabolism.
Methods. Literature reviews were conducted through the survey of the literature utilizing the Pubmed 
electronic databases, with the aim to identify all literature regarding the metabolic effects of valproic acid. 
This review has been written to summarize the latest evidence of valproic acid’s effects on lipid profiles.
Review and Discussion. The possible mechanisms of valproic acid-related changes of lipid profiles could 
be through insulin resistance and hyperinsulinemia in several ways, resulting in the alteration of lipogen-
esis and clearance of triglyceride and lipoproteins.
Conclusion. The effect of valproic acid on lipid profiles is complex and there is a need for further investi-
gation. Consequently the monitoring and follow up of lipid profiles from patients prescribed valproic acid 
is recommended.
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INTRODUCTION
Valproic acid (2-propylpentanoic acid) is a branched-
short-chain fatty acid derived from valeric acid which 
is extracted from Valeriana officinalis (Fan et al., 2016; 
Tomson et al., 2016). Valproic acid is commonly used for 
the treatment of epilepsy, psychiatric disorders such as 
bipolar disorder and anxiety and prophylaxis of a mi-
graine (Ghodke-Puranik et al., 2013; Terbach and Wil-
liams, 2009; Tseng et al., 2017).
Valproic acid is well absorbed and has a very high 
ability to bind to albumin (87–95%), with the conse-
quence being that there is a small part of valproic acid 
excreted by the kidneys (6–20 ml/day/kg body weight) 
(Silva et al., 2008). The plasma therapeutic levels of 
the long-term use of valproic acid are approximately 
40–100 µg/ml or 280–700 µmol/L (Silva et al., 2008). 
Most of the valproic acid will be biotransformed en-
dogenously through three mechanisms: 1) glucuroni-
dation; 2) beta-oxidation in the mitochondria; and 3) 
P450 cytochrome-mediated oxidation (Ghodke-Pu-
ranik et al., 2013).
The side effects of valproic acid vary, and include 
sedation, fatigue, tremor, gastrointestinal symptoms, 
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and weight gain (Chen et al., 2014; Tomson et al., 2016). 
Long-term use of valproic acid is associated with met-
abolic disorders such as hyperinsulinemia, insulin re-
sistance, hyperleptinemia and leptin resistance result-
ing in weight gain, dyslipidemia, menstrual irregular-
ities, hyperandrogenism and polycystic ovarian syn-
drome (Belcastro et al., 2013).
Dyslipidemia is known to be an important risk fac-
tor for atherosclerosis. Cholesterol has an important 
role in the process of atherosclerosis by increasing en-
dothelial permeability, lipoprotein retention in blood 
vessels, recruitment of inflammatory cells and the for-
mation of foam cells (Belcastro et al., 2013; Sakakura et 
al., 2013). Berenson et al. (1992) showed that there was 
a positive correlation between total cholesterol levels 
and atherosclerosis at a young age. Total cholesterol in-
creases the risk of coronary heart disease by 2.52 (95% 
confidence interval: 1.15–5.07) in men and 3.20 (1.44–
7.09) in women (Nagasawa et al., 2012). Epidemiologi-
cal data show that there is an increase of the prevalence 
and death rates from atherosclerosis in adults with epi-
lepsy (19% for all cases of epilepsy and 22,5% for idio-
pathic epilepsy) (Annegers et al., 1984).
The effect of valproic acid on lipid profiles is con-
troversial (Belcastro et al., 2013). Several studies have 
found that valproic acid does not affect total choles-
terol levels, as well as other lipid profiles (Belcastro et 
al., 2013; Luo et al., 2015; Płonka-Półtorak et al., 2016), 
while other studies have shown significant changes in 
lipid, lipoprotein and apolipoprotein profiles (Auley 
and Mooney, 2015; Belcastro et al., 2013; Erdemir et al., 
2009; Luo et al., 2015). Regarding these circumstances, 
herewith we discuss the putative mechanisms of the ef-
fect of valproic acid on lipid profiles.
AIM
To summarize and discuss the potential mechanism 
of valproic acid-related changes of lipid profiles so as 
to get a better understanding of the side effects of val-
proic acid on lipid metabolism.
METHODS
Literature reviews were conducted through a search 
utilizing the Pubmed electronic databases www.ncbi.
nlm.nih.gov/pubmed during June to July 2018, with 
the aim of identifying all literature regarding the met-
abolic effect of valproic acid using keywords such as 
valproate, metabolic syndrome, lipid profiles, lipopro-
teins, and cholesterol. This review has been written to 
summarize the latest evidence of valproic acid’s effects 
in lipid profiles.
REVIEW AND DISCUSSION
Long-term use of valproic acid is associated with met-
abolic disorders such as hyperinsulinemia, insulin re-
sistance, hyperleptinemia and leptin resistance result-
ing in weight gain, dyslipidemia, menstrual irregular-
ities, hyperandrogenism and polycystic ovarian syn-
drome (Belcastro et al., 2013).
The role of valproic acid in lipid profiles is controver-
sial (Belcastro et al., 2013), and nowadays, there is no 
exact data regarding the putative mechanisms of these 
effects, even when it is clear that valproic acid has an ef-
fect on weight gain, which is observed during the first 
3 months of therapy, reaching its maximum effect af-
ter 6 months. A long duration of therapy is associated 
with significant weight gain that continues after the 
first rapid increase in the first months of therapy. Al-
though not all studies have analyzed the role of valp-
roic acid dosage, literature has demonstrated that there 
an no correlations between the degree of weight gain 
and the daily valproic acid dosage and/or serum valp-
roic acid concentration (Verrotti et al., 2009).
Abaci et al. (2009) demonstrated that valproic acid 
increases total cholesterol and low-density lipoprotein 
(LDL) cholesterol levels after 12 months of use, on the 
other hand, Wahyuni  and Was’an (2013) reported that 
there was only a weak correlation between the duration 
of use of first-generation antiepileptic drugs (phenyto-
in, carbamazepine, and valproic acid) and total choles-
terol levels and triglycerides (r = 0.3).
Dyslipidemia is known to be an important risk fac-
tor for atherosclerosis. Cholesterol has an important 
role in the process of atherosclerosis by increasing en-
dothelial permeability, lipoprotein retention in blood 
vessels, recruitment of inflammatory cells and the for-
mation of foam cells (Belcastro et al., 2013; Sakakura et 
al., 2013). Luo et al. (2015) demonstrated that the aver-
age carotid artery intima-media thickness (CA-IMT) of 
epileptic patients treated with valproic acid was high-
er than that of healthy people. This study provides ev-
idence that valproic acid might contribute to the pro-
cess of atherosclerosis.
The mechanism of lipid profile changes due to val-
proic acid is still unclear. A possible mechanism may 
be through the insulin resistance and hyperinsuline-
mia, resulting in impaired lipid transport and lipogen-
esis (Abaci et al., 2009).
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Insulin is a peptide hormone secreted by pancreat-
ic beta cells that control the synthesis and storage of 
lipids in the liver. Insulin increases de novo lipogene-
sis, esterification and triglyceride secretion in the liv-
er. Additionally, it also inhibits fatty acid oxidation and 
lipolysis (Titchenell et al., 2017). Insulin inhibits lipoly-
sis in the adipocytes by activating the phosphoinositol-
3-kinase signal which provides catecholamine inhibi-
tory effects in the lipolysis, resulting in reduced levels 
of free fatty acids and glycerol in the circulation (Bel-
castro et al., 2013). Insulin plays a role in the process of 
triglyceride clearance through lipoprotein lipase (LPL) 
activation and triglyceride output through its effect on 
synthesis and secretion of very low-density lipoprotein 
(VLDL) in the liver.
Valproic acid causes hyperinsulinemia in several 
ways (Figure 1). Valproic acid causes hyperinsuline-
mia and insulin resistance by affecting several organs 
or tissues, such as adipose tissue, hypothalamus, pitu-
itary and pancreatic beta cells (Belcastro et al., 2013).
The use of valproic acid causes hypothalamic dys-
regulation due to an increase in gamma-aminobutyr-
ic acid (GABA) transmission in the hypothalamic ax-
is, which results in an increase of appetite with a con-
sequences being the increase of cholesterol and carbo-
hydrate intake (Verrotti et al., 2009). Egger and Brett 
(1981) reported that there was weight gain in 44 of the 
100 children treated with valproic acid. Increased ap-
petite and excessive weight gain also were reported in 
31 of 66 patients with generalized epilepsy and 13 of 34 
with partial epilepsy treated with valproic acid. These 
numbers were significantly increased within a year af-
ter valproic acid treatment (37.5%) compared to other 
antiepileptic drugs (10%) (Egger and Brett, 1981). The 
composition of lipids in the liver is derived from food 
(15%), de novo synthesis (30%), and adipose tissues 
(60%) (Sozio et al., 2010).
The effect of dietary cholesterols on plasma choles-
terol levels is still controversial. Several studies have 
shown that dietary cholesterols increase LDL choles-
terol levels. (Auley and Mooney, 2015). Other studies 
reported that dietary cholesterols have a minimal effect 
on plasma cholesterol levels. On the other hand, a me-
ta-analysis showed that dietary cholesterols do not af-
fect plasma cholesterol levels (Alphonse et al., 2017).













































Figure 1. The putative mechanisms of valproic acid-related changes of lipid profiles (by Santoso Jaeri, 
unpublished data). GLUT-1 – Glucose Transporter-1; LDL – Low Density Lipoprotein; ALP-4 – Angiopoetin-
Like Protein-4; HDL – High Density Lipoprotein; VLDL – Very Low Density Lipoprotein.
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levels resulting in an elevated level of insulin. This phe-
nomenon will cause the conversion of carbohydrates to 
triglycerides through the breakdown of acetyl Co-A in 
the cycle of fatty acid synthesis (Sozio et al., 2010).
Valproic acid increases the expression of resistin and 
a fasting-induced adipose factor known as angiopoie-
tin-like protein-4 (ALP-4). Both proteins contribute to 
insulin resistance (Belcastro et al., 2013).
Resistin is a member of the resistin-like molecule 
(RELM) family of cysteine-rich proteins. Resistin is 
secreted in the form of trimers or hexamers by adipo-
cytes in rodents and monocytes/macrophages in hu-
mans (Wang et al., 2017). In addition, resistin is also 
produced in the ventromedial nucleus, and hippocam-
pus (Bacloer et al., 2015). The structure of resistin mole-
cule in humans is a polypeptide with a molecular weight 
of 10-kDa. Resistin contains 108 amino acids with 16 
peptide signal residues (Park et al., 2017). The role of 
resistin in the pathogenesis of obesity-mediated insu-
lin resistance and type 2 diabetes is still unclear. In ro-
dents, it has been shown that resistin causes severe he-
patic insulin resistance through several ways such as in-
creasing the expression of pro-inflammatory cytokines, 
inhibiting the 5’ adenosine monophosphate-activated 
protein kinase (AMPK) phosphorylation and inducing 
the suppressor of cytokine signaling 3 (SOCS3) (Huang 
and Yang, 2016). Resistin also reduces gene expression 
encoding for hepatic gluconeogenesis enzymes (Antu-
na-Puentea et al., 2008).
 Angiopoietin-like protein-4 (ALP-4) is one of the 
angiopoietin-like proteins that play a role in the home-
ostasis of lipid and glucose metabolism (Li and Teng, 
2014). ALP-4 has a molecular weight of 45–65 kDa. 
ALP-4 is composed of glycoproteins and 406 amino ac-
ids. An increase in the expression of ALP-4 causes an 
increase in triglyceride and cholesterol levels (Groot-
aert et al., 2012).
Valproic acid also has an effect on other adipokines 
released by the adipose tissue such as adiponectin, lep-
tin, leptin receptors and ghrelin (Verrotti et al., 2009). 
Adiponectin has a role in regulating the metabolism of 
glucose and lipids (Huang and Yang, 2016). Adiponectin 
decreases the gluconeogenesis process to prevent hyper-
glycemia (Li et al., 2013). Valproic acid inhibits adiponec-
tin expression through the inhibition of histone deacet-
ylases (HDAC) resulting in an increased gluconeogene-
sis process. The suppression of these expressions caus-
es an increase of fatty acid oxidation and insulin resist-
ance associated with valproic acid (Belcastro et al., 2013).
Valproic acid is a branched short-chain fatty acid. It 
has a high affinity to albumin, competing with free fat-
ty acids to bind to albumin hence causing an increase 
in free fatty acid levels. Increased availability of free 
fatty acids in the blood, in turn, modulates insulin se-
cretion (Verrotti et al., 2009).
Valproic acid also affects directly the pancreatic be-
ta cells to secrete insulin, resulting in an inappropriate 
level of insulin. The mechanism of secretion of insulin 
by beta cells is complex and dependent on many factors. 
Valproic acid increases the oxidative stress state of be-
ta cells resulting in its dysfunction. Beta cells are sen-
sitive to reactive oxygen species (ROS) and reactive ni-
trogen species (RNS) because they are low in free-rad-
ical quenching (antioxidant) enzymes such as catalase, 
glutathione peroxidase, and superoxide dismutase. Ox-
idative stress in the beta cells has the ability to damage 
mitochondria, which impairs the impaired the mito-
chondrial processes involved in glucose-mediated in-
sulin secretion (Evans et al., 2003).
Hyperinsulinemia by valproic acid also results from 
the effects of valproic acid on insulin-mediated intra-
cellular glucose transport. Intracellular glucose trans-
port is assisted by five glucose-carrying proteins, one 
of which is Glucose transporter-1 (GLUT-1). GLUT-1 is 
an integral membrane protein that is present in most 
of the boundaries between blood vessels and tissues. It 
plays a role in the basal energy supply of the network. 
The conformational model of GLUT-1 is composed of 
the 12 α-helical transmembrane segments, the amino 
and carboxy intracellular terminals, the intracellular 
loop, and the extracellular loop consisting of the N-gly-
cosylation site (Klepper and Voit, 2002). Valproic acid 
can inhibit GLUT-1 activity, thereby reducing intracel-
lular glucose transport and decreasing the expression 
of GLUT-1 mRNA. A decrease in intracellular glucose 
transport causes an increase in blood glucose levels that 
can stimulate insulin secretion (Verrotti et al., 2009).
CONCLUSION AND FUTURE PERSPECTIVES
In conclusion, although the relationship between val-
proic acid and GABA action is generally accepted, the 
relationship between valproic acid and lipid profile 
changes have not been fully elucidated. There are po-
tential complex mechanisms of valproic acid on lipid 
profiles. In order to determine the exact molecular as-
pects of the fundamental physiological mechanisms of 
these events, further studies are needed. There are sev-
eral challenges such as identifying the genes which are 
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responsible for these effects. In further studies, the use 
of models such as experimental animals might be nec-
essary since there are many confounding factors when 
the studies were carried out on human subjects. Anoth-
er issue is that because there are an increase of dyslipi-
demia cases on a patient using valproic acid, the moni-
toring and follow up of lipid profiles from patients pre-
scribed valproic acid should be considered.
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